Enhancing Kidney Function Assessment: The Shift to Race-Free eGFR Calculations and the Role of Cystatin C

Enhancing Kidney Function Assessment: The Shift to Race-Free eGFR Calculations and the Role of Cystatin C

The assessment of kidney function is a critical component of modern healthcare, particularly in the context of chronic kidney disease (CKD). With growing concerns regarding the accuracy and equity of traditional estimation methods, the clinical community is increasingly turning towards more reliable and inclusive approaches. This article explores the implications of implementing the CKD-EPI 2021 race-free estimated glomerular filtration rate (eGFR) calculation and the role of cystatin C as a confirmatory test, providing insights into effective practices for clinical laboratories and healthcare providers.

Understanding eGFR and Its Importance

The eGFR is a widely used measure to assess kidney function, calculated primarily from serum creatinine levels. While this method has been standard for decades, it has its limitations, particularly regarding accuracy and fairness across diverse populations. The traditional eGFR formulas, which often incorporate race as a factor, may inadvertently lead to disparities in diagnosis and treatment outcomes.

The CKD-EPI 2021 race-free eGFR calculation addresses these shortcomings by providing a more equitable assessment tool that does not rely on race, thereby aiming to eliminate biases in kidney disease diagnosis. This adaptation is crucial in ensuring that all patients receive appropriate care based on their actual kidney function rather than potentially misleading estimates.

The Role of Cystatin C

In conjunction with the new eGFR calculations, cystatin C has emerged as a valuable biomarker for assessing kidney function. Cystatin C is a protein produced by all nucleated cells and is filtered by the kidneys. Its levels in the blood are less influenced by factors such as muscle mass and dietary protein intake, making it a more reliable indicator of glomerular filtration rate (GFR) in certain populations.

Clinical practice recommendations suggest that cystatin C should be ordered as a confirmatory test for patients with an eGFR based on creatinine (eGFRcr) of 45-59 mL/min/1.73m² and a urine albumin-to-creatinine ratio (uACR) of less than 30 mg/g. This approach is particularly beneficial for patients for whom serum creatinine may not provide an accurate representation of kidney function, such as the elderly or those with reduced muscle mass. The use of eGFRcr-cys, which combines both creatinine and cystatin C measurements, offers a more precise estimate of GFR, thus enhancing patient care.